(Q37103923)

18 August 2017

1 reference

title

Current progress of DNA vaccine studies in humans (English)

1 reference

18 August 2017

1 reference

Shan Lu

1

1 reference

PubMed ID

18324888

18 August 2017

Shixia Wang

series ordinal

2

1 reference

PubMed ID

18324888

18 August 2017

Jill M Grimes-Serrano

series ordinal

3

1 reference

18 August 2017

1 March 2008

1 reference

Expert Review of Vaccines

18 August 2017

1 reference

18 August 2017

7

1 reference

18 August 2017

2

1 reference

18 August 2017

175-191

1 reference

Genetic immunization is a simple method for eliciting an immune response

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Gene inoculation generates immune responses against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

DNA immunization protects nonhuman primates against rabies virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Immunization with DNA through the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Induction of immune responses by DNA vaccines in large animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Electroporation for targeted gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Prime boost vaccines power up in people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.175

21 January 2018

Identifiers

DOI

10.1586/14760584.7.2.175

1 reference

18 August 2017

1 reference

PubMed ID

18324888